Your browser doesn't support javascript.
loading
Rotavirus Vaccine Impact since Its Introduction in the National Immunization Program of Argentina.
Marti, Sebastian Garcia; Gibbons, Luz; Reidel, Sara; Stupka, Juan; Degiuseppe, Juan; Argento, Fernando; Gómez, Jorge A.
Afiliação
  • Marti SG; Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina. sgarciamarti@iecs.org.ar.
  • Gibbons L; Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
  • Reidel S; Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
  • Stupka J; Laboratorio Nacional de Referencia Para Rotavirus y Norovirus, INEI-ANLIS, Dr. Carlos G. Malbran, ANLIS, Buenos Aires, Argentina.
  • Degiuseppe J; Laboratorio Nacional de Referencia Para Rotavirus y Norovirus, INEI-ANLIS, Dr. Carlos G. Malbran, ANLIS, Buenos Aires, Argentina.
  • Argento F; Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
  • Gómez JA; GSK, Buenos Aires, Argentina.
Infect Dis Ther ; 12(2): 513-526, 2023 Feb.
Article em En | MEDLINE | ID: mdl-36520328
ABSTRACT

INTRODUCTION:

Rotavirus (RV) is the most common cause of childhood diarrhea. Argentina introduced RV vaccination in the National Immunization Program in January 2015. This study evaluates the impact of RV vaccine implementation on the burden of acute diarrheal disease (ADD) and RV positive cases, and hospitalizations among children in Argentina.

METHODS:

A counterfactual time-series analysis was performed. Data on ADD (2013-2018) and RV diarrhea (2012-2018) cases in children aged < 5 years were collected from the National Healthcare Surveillance System (clinical and laboratory data). Data on hospital discharges following ADD and RV diarrhea (2011-2017) were retrieved from the Health Statistics and Information Office. All data were classified by the age groups < 1 year, < 2 years, 2-5 years. Vaccine impact was defined as the difference between the predicted time trend (simulated using 2012-2014 data) and the actual post-vaccination data (2015-2018).

RESULTS:

A significant reduction of 22.1% of notified ADD cases and 15.4% of hospital discharges following ADD among children < 2 years was observed in the 3 years after RV vaccine implementation. Data also showed a significant decline of 54.0% and 59.4% of notified RV cases in children < 2 and < 1 years, respectively, and a reduction of 39.3% and 40.8% in RV hospital discharges for the same age groups.

CONCLUSION:

This study shows a significant reduction in notified ADD cases and RV cases and hospital discharges following ADD and RV cases in children < 2 years after RV vaccine introduction in Argentina in 2015.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE País/Região como assunto: America do sul / Argentina Idioma: En Revista: Infect Dis Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Argentina

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE País/Região como assunto: America do sul / Argentina Idioma: En Revista: Infect Dis Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Argentina